| Pyelonephritis
Recarbrio vs Zerbaxa
Side-by-side clinical, coverage, and cost comparison for pyelonephritis.Deep comparison between: Recarbrio vs Zerbaxa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZerbaxa has a higher rate of injection site reactions vs Recarbrio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zerbaxa but not Recarbrio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Recarbrio
Zerbaxa
At A Glance
IV infusion
Every 6 hours
Carbapenem + beta-lactamase inhibitor
IV infusion
Every 8 hours
Cephalosporin/beta-lactamase inhibitor
Indications
- Hospital acquired bacterial pneumonia
- VABP
- Complicated urinary tract infection
- Pyelonephritis
- Complicated intra-abdominal infection
- Peritonitis
- Urinary tract infection
- Pyelonephritis
- Hospital acquired pneumonia
- VABP
Dosing
Hospital acquired bacterial pneumonia, VABP, Complicated urinary tract infection, Pyelonephritis, Complicated intra-abdominal infection Adults with CLcr >=90 mL/min: 1.25 g (imipenem 500 mg/cilastatin 500 mg/relebactam 250 mg) IV infusion over 30 minutes every 6 hours for 4-14 days; dose reduction required for CLcr <90 mL/min; pediatric patients (>=2 kg): weight- and age-based dosing of 37.5 mg/kg every 6-8 hours IV.
Peritonitis 1.5 g IV every 8 hours over 1 hour for 4 to 14 days, used in conjunction with metronidazole 500 mg IV every 8 hours; pediatric patients: 30 mg/kg up to 1.5 g every 8 hours for 5 to 14 days.
Urinary tract infection, Pyelonephritis 1.5 g IV every 8 hours over 1 hour for 7 days; pediatric patients: 30 mg/kg up to 1.5 g every 8 hours for 7 to 14 days.
Hospital acquired pneumonia, VABP 3 g IV every 8 hours over 1 hour for 8 to 14 days in adult patients 18 years and older.
Contraindications
- Severe hypersensitivity (e.g., anaphylaxis) to any component of RECARBRIO
- Known serious hypersensitivity to components of ZERBAXA (ceftolozane and tazobactam), piperacillin/tazobactam, or other members of the beta-lactam class
Adverse Reactions
Most common (>=4%) Anemia, diarrhea, AST increased, ALT increased, hypokalemia, hyponatremia, constipation, pyrexia, rash
Serious Hypersensitivity reactions, seizures and other CNS adverse reactions, Clostridioides difficile-associated diarrhea
Most common (>=5%) Nausea, diarrhea, headache, pyrexia
Serious Hypersensitivity reactions, Clostridioides difficile-associated diarrhea, intracranial hemorrhage, renal impairment/renal failure, hepatic transaminase increased
Pharmacology
RECARBRIO combines imipenem (a carbapenem that inhibits bacterial cell wall synthesis by binding PBP 2 and PBP 1B), cilastatin (a renal dehydropeptidase inhibitor that prevents renal metabolism of imipenem), and relebactam (a diazabicyclooctane beta-lactamase inhibitor that protects imipenem from degradation by serine beta-lactamases including KPC, AmpC-type PDC, SHV, TEM, and CTX-M enzymes).
Ceftolozane is a cephalosporin antibacterial that inhibits bacterial cell wall biosynthesis by binding to penicillin-binding proteins (PBPs); tazobactam is an irreversible beta-lactamase inhibitor that extends ceftolozane activity against beta-lactamase-producing organisms.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Recarbrio
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (6/12) · Qty limit (0/12)
Zerbaxa
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (6/12) · Qty limit (0/12)
UnitedHealthcare
Recarbrio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Zerbaxa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Recarbrio
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Zerbaxa
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Recarbrio.
No savings programs available for Zerbaxa.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RecarbrioView full Recarbrio profile
ZerbaxaView full Zerbaxa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.